Skip Navigation

Annals of Oncology 2005 16(Supplement 6):vi25-vi30; doi:10.1093/annonc/mdi455
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vokes, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vokes, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Articles

Current treatments and promising investigations in a multidisciplinary setting

E. Vokes*

University of Chicago Medical Center, University of Chicago, Illinois, USA

* Correspondence to: Dr E. Vokes, University of Chicago Medical Center, University of Chicago, 5841 S Maryland Ave MC 2115, Chicago, IL-60637–1470, USA. Tel: +1 773 834 3093; Fax: +1 773 702 3002; E-mail: evokes{at}medicine.bsd.uchicago.edu

The care of the patient with squamous cell carcinoma of the head and neck (SCCHN) requires a multidisciplinary approach. For many years, radiotherapy following surgery was considered the standard approach to the treatment of locally advanced resectable disease. Data from randomized trials have confirmed the benefits of concurrent chemotherapy and radiotherapy (chemoradiotherapy) in this setting and this is now the gold standard for treatment. Chemoradiotherapy is also the recommended approach for unresectable disease. Neoadjuvant chemotherapy has been useful in resectable disease where organ preservation is desirable, but a concomitant approach is superior. Although survival benefits have not been consistently demonstrated, the theoretical potential of this approach has lead to continued investigations using newer agents, such as the taxanes. Novel targeted agents, such as antagonists of the epidermal growth factor receptor (EGFR), are showing promise in the treatment of patients with both locally advanced and recurrent/metastatic SCCHN. Treatment issues that require immediate attention include identifying optimal chemoradiotherapy regimens, clarifying the role of neoadjuvant chemotherapy, defining the optimal integration of targeted therapies into combined modality approaches and identifying useful prognostic and predictive factors.

Key words: Cetuximab, chemoradiotherapy, EGFR, neoadjuvant, SCCHN, targeted therapies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. X. Wang, A. Bao, S. J. Herrera, W. T. Phillips, B. Goins, C. Santoyo, F. R. Miller, and R. A. Otto
Intraoperative 186Re-Liposome Radionuclide Therapy in a Head and Neck Squamous Cell Carcinoma Xenograft Positive Surgical Margin Model
Clin. Cancer Res., June 15, 2008; 14(12): 3975 - 3983.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. M. Lell, C. Gmelin, C. Panknin, K. T. Eckel, M. Schmid, W. A. Bautz, and H. Greess
Thin-Slice MDCT of the Neck: Impact on Cancer Staging
Am. J. Roentgenol., March 1, 2008; 190(3): 785 - 789.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.